DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
email sent successfully
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Horizon Therapeutics Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application for Active Thyroid Eye Disease Treatment
Horizon Therapeutics plc today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for teprotumumab, an investigational medicine for the treatment of active thyroid eye disease (TED), and granted it Priority Review designation. The FDA grants Priority Review designation to applications for medicines that have the potential to provide significant improvements in the treatment of serious conditions. Priority Review is associated with an accelerated six-month review period compared to the standard ten-month review period. If approved, teprotumumab would be the first FDA-approved medicine for the treatment of active TED.
“Priority Review for the teprotumumab BLA is another positive step toward our goal to make a difference in the lives of people who are living with active TED – a painful, debilitating and vision-threatening rare disease,” said Timothy Walbert, Chairman, President and Chief Executive Officer, Horizon.
Videos & VisualsEyes on Graves’: LaQuilla’s Storyhttps://www.youtube.com/watch?v=98tJEN1C...
Evidence & EducationGraves’ Orbitopathy: Reevaluating Rundle’s CurveGraves’ orbitopathy (GO) is the most c...
Evidence & EducationPsychological Disturbance in Graves’ OphthalmopathyObjective: To study mood disturbance in...
Evidence & EducationMycophenolate Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-Severe Graves’ Or...Background: European guidelines recomme...
People & PlacesAnna L. Mitchell, MBBS hons, MRes, MRCP, PhDDr. Anna Mitchell is associated as Acade...
Videos & VisualsENFOQUE en la salud ocularhttps://www.onegravesvoice.com/wp-conten...
Videos & VisualsQuality of Life Remains Poor in People With Thyroid Eye Diseasehttps://www.youtube.com/watch?v=fwYlJ_pt...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.